Merck has issued revised labeling for its COX-2 inhibitor rofecoxib (Vioxx) that incorporate findings from the 8,000-patient VIGOR (Vioxx Gastrointestinal Outcomes Research) study.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Revised rofecoxib labeling adds GI safety benefit, cardiovascular risk

Newsletter